Trial Profile
A Phase I/II Study of Ado-Trastuzumab Emtansine (T-DM1) + ABT-737 in Treating Patients With HER2(+) Breast Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jun 2014
Price :
$35
*
At a glance
- Drugs ABT 737 (Primary) ; Trastuzumab emtansine
- Indications Breast cancer
- Focus Adverse reactions
- 30 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to withdrawn prior to recruitment.
- 19 Mar 2014 New trial record